Tumor‐infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer

Tumor‐infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer

Abstract Background Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that is treated with chemotherapy. Recently, programmed death 1 (PD1) inhibition, as well as antibody‐drug conjugates, have been added to the available treatment regimen, yet metastatic disease is fatal....

Full description

Bibliographic Details
Main Authors: Arielle Jacover, Yonaton Zarbiv, Keidar Haran Tal, Shira Klein, Shani Breuer, Ronen Durst, Batia Avni, Sigal Grisariu, Polina Stepensky, Michal Lotem, Ofra Maimon, Tamar Yablonski‐Peretz
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Reports
Subjects:
adoptive cell therapy
triple negative breast cancer
tumor infiltrating lymphocyte
Online Access:https://doi.org/10.1002/cnr2.1894

Internet

https://doi.org/10.1002/cnr2.1894

Similar Items